Press Briefing: Patient Education and the Latest Medications Improve the Management of Schizophrenia

-- Press Briefing --

Patient education and the latest medications, such as SEROQUEL(r) (quetiapine fumarate) tablets, improve the management of schizophrenia

WHAT: Leading researchers show that patient education and the latest medications, such as SEROQUEL(r) (quetiapine fumarate) tablets, are improving the management of schizophrenia and changing lives

WHEN: Monday, June 1, 1998 9:45 am to 10:30 am

WHERE: The American Psychiatric Association Annual Meeting
Press Briefing Room
Communications Center, Room 101, Lower Level
Convention Center
Toronto, Canada

WHO:

Amir H. Kalali, MD Assistant Clinical Professor, University of California at Irvine A recent multinational survey of patient satisfaction shows that patients on antipsychotic treatment have an overwhelming rate of satisfaction with and acceptability for long-term treatment with SEROQUEL

Jamie A. Mullen, MD Associate Medical Director, Medical Affairs, Zeneca Pharmaceuticals Overview of recent data on SEROQUEL(r); a case history approach demonstrating the power of this recent treatment to change lives

Richard Jed Wyatt, MD Chief, Neuropsychiatry Branch, National Institutes of Health Introduction to "Critical Connections," a unique educational video produced by the American Psychiatric Association and Zeneca Pharmaceuticals, designed to help patients and their families cope with the devastating effects of schizophrenia
-- Brief video synopsis of "Critical Connections" -- the only video tool to date featuring patients with schizophrenia

For more information or to schedule an interview, please contact:

Rachel Bloom, 302/886-7858, rachel.bloom@phwilm.zeneca.com
Robert Couter, 312/329-7514, (cell: 312/401-6142), robert_couter@bm.com
Julie King, 312/494-4932, (cell: 312/213-2704), julie_king@bm.com

Note: Cell phones will be active during the meeting (Saturday, May 30, to Tuesday, June 2)